Data Year:

For its 2024 fiscal year, BIOMARIN PHARMACEUTICAL INC, listed the following executives on its annual proxy statement to the SEC

Equity
Cash Compensation
Other
Fiscal Year Ended in 2024
Name And Title Total Compensation Pay Rank By Title In Biotechnology industry
G. Eric Davis
Executive Vice President, Chief Legal Officer
Total Compensation $5,058,665 View details Pay Rank By Title In Biotechnology industry #40 View more
Henry J. Fuchs M.D.
Former President, Worldwide Research & Development
Total Compensation $8,127,856 View details Pay Rank By Title In Biotechnology industry #4 View more
Brian R. Mueller
Executive Vice President, CFO
Total Compensation $5,498,568 View details Pay Rank By Title In Biotechnology industry #42 View more
Alexander Hardy
President and CEO
Total Compensation $14,853,605 View details Pay Rank By Title In Biotechnology industry #48 View more
Gregory R. Friberg M.D.
Executive Vice President, Chief Research & Development Officer
Total Compensation $7,221,559 View details Pay Rank By Title In Biotechnology industry #21 View more
Cristin Hubbard
Executive Vice President, Chief Commercial Officer
Total Compensation $6,928,261 View details Pay Rank By Title In Biotechnology industry #24 View more

The charts on this page feature a breakdown of the total annual pay for the top executives at BIOMARIN PHARMACEUTICAL INC as reported in their proxy statements.

Total Cash Compensation information is comprised of yearly Base Pay and Bonuses. BIOMARIN PHARMACEUTICAL INC income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. BIOMARIN PHARMACEUTICAL INC annual reports of executive compensation and pay are most commonly found in the Def 14a documents.

Total Equity aggregates grant date fair value of stock and option awards and long term incentives granted during the fiscal year.

Other Compensation covers all compensation-like awards that don't fit in any of these other standard categories. Numbers reported do not include change in pension value and non-qualified deferred compensation earnings.

Name And Title Total Cash Equity Other Total Compensation
G. Eric Davis
Executive Vice President, Chief Legal Officer
Total Cash $1,287,615 Equity $3,748,054 Other $22,996 $5,058,665
Henry J. Fuchs M.D.
Former President, Worldwide Research & Development
Total Cash $1,440,761 Equity $6,661,839 Other $25,256 $8,127,856
Brian R. Mueller
Executive Vice President, CFO
Total Cash $1,312,581 Equity $4,163,189 Other $22,798 $5,498,568
Alexander Hardy
President and CEO
Total Cash $2,551,500 Equity $12,152,534 Other $149,571 $14,853,605
Gregory R. Friberg M.D.
Executive Vice President, Chief Research & Development Officer
Total Cash $534,606 Equity $6,584,234 Other $102,719 $7,221,559
Cristin Hubbard
Executive Vice President, Chief Commercial Officer
Total Cash $1,474,246 Equity $5,161,068 Other $292,947 $6,928,261
For its 2024 fiscal year, BIOMARIN PHARMACEUTICAL INC, listed the following CEO pay ratio data on its annual proxy statement to the SEC.
CEO Name CEO Pay Median Employee Pay CEO Pay Ratio
Alexander Hardy CEO Pay $14,853,605 Median Employee Pay $176,090 CEO Pay Ratio 84:1
For its 2024 fiscal year, BIOMARIN PHARMACEUTICAL INC, listed the following board members on its annual proxy statement to the SEC.
Name Total COMPENSATION
Athena Countouriotis, M.D. Total Cash $445,045
Barbara W. Bodem Total Cash $461,170
David E.I. Pyott, M.D. (Hon.) Total Cash $458,045
Dennis J. Slamon, M.D., Ph.D. Total Cash $37,500
Elaine J. Heron, Ph.D. Total Cash $458,545
Elizabeth McKee Anderson Total Cash $463,545
Jean-Jacques Bienaimé Total Cash $1,368,831
Mark J. Alles Total Cash $49,250
Mark J. Enyedy Total Cash $461,170
Maykin Ho, Ph.D. Total Cash $467,045
Richard A. Meier Total Cash $719,067
Robert J. Hombach Total Cash $467,045
V. Bryan Lawlis, Ph.D. Total Cash $42,500
Willard Dere, M.D. Total Cash $463,045
Browse Board of Directors By First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Executives by First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Companies by Company Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

This report is not for commercial use. Thorough reviews have been conducted to assure this data accurately reflects disclosures. However for a complete and definitive understanding of the pay practices of any company, users should refer directly to the actual, complete proxy statement.

Use of Data / Disclaimer

The information shown here is a reporting of information included in the company's proxy statement. The proxy statement includes footnotes and explanations of this information plus other information that is pertinent in assessing the overall value and appropriateness of the compensation information. For those interested in conducting a detailed compensation analysis, we recommend that you review the entire proxy statement. You may retrieve the full proxy statement by going to the Securities and Exchange Commission (SEC) website at www.sec.gov and entering the company's name and then looking in the first column for an entry of "Form DEF 14A" (or any similar code). You may also find the annual proxy statement by going directly to the company's website.

What is a proxy statement?

A proxy statement (or "proxy") is a form that every publicly traded U.S. company is required to file with the U.S. Securities & Exchange Commission (SEC) within 120 days after the end of its fiscal year. The proxy must be sent to every shareholder in advance of the company's annual shareholders meeting. All proxy statements are public filings made available to the general public by the SEC.

The proxy statement's main purpose is to alert shareholders to the annual meeting and provide them information about the issues that will be voted on during the annual meeting, including decisions such as electing directors, ratifying the selection of auditors, and other shareholder-related decisions, including shareholder-initiated initiatives. Also, proxies must disclose specific detailed information regarding the pay practices for certain executives.